Role of long noncoding RNAs in pathological cardiac remodeling after myocardial infarction: An emerging insight into molecular mechanisms and therapeutic potential

Biomed Pharmacother. 2024 Mar:172:116248. doi: 10.1016/j.biopha.2024.116248. Epub 2024 Feb 6.

Abstract

Myocardial infarction (MI) is the leading cause of heart failure (HF), accounting for high mortality and morbidity worldwide. As a consequence of ischemia/reperfusion injury during MI, multiple cellular processes such as oxidative stress-induced damage, cardiomyocyte death, and inflammatory responses occur. In the next stage, the proliferation and activation of cardiac fibroblasts results in myocardial fibrosis and HF progression. Therefore, developing a novel therapeutic strategy is urgently warranted to restrict the progression of pathological cardiac remodeling. Recently, targeting long non-coding RNAs (lncRNAs) provided a novel insight into treating several disorders. In this regard, numerous investigations have indicated that several lncRNAs could participate in the pathogenesis of MI-induced cardiac remodeling, suggesting their potential therapeutic applications. In this review, we summarized lncRNAs displayed in the pathophysiology of cardiac remodeling after MI, emphasizing molecular mechanisms. Also, we highlighted the possible translational role of lncRNAs as therapeutic targets for this condition and discussed the potential role of exosomes in delivering the lncRNAs involved in post-MI cardiac remodeling.

Keywords: Cardiac fibrosis; Cardiac regeneration; Cardiac remodeling; Exosome; Heart failure; Long non-coding RNA; Regenerative medicine; Translational medicine.

Publication types

  • Review

MeSH terms

  • Heart Failure* / genetics
  • Humans
  • Myocardial Infarction* / genetics
  • Myocytes, Cardiac
  • RNA, Long Noncoding* / genetics
  • Ventricular Remodeling / genetics

Substances

  • RNA, Long Noncoding